22 July 2026
: Case report 
Diagnostic Challenges and Scientific Management of Suspected Recurrent Kikuchi-Fujimoto Disease: A Case Report
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
YanLin Yang
ABCDEF 1*, Chao Wang ABCDEF 2
DOI: 10.12659/AJCR.952658
Am J Case Rep 2026; 27:e952658
Table 1 Laboratory data of patient on admission and prior to discharge.
| Variables | On admission | Prior to discharge | Reference range |
|---|---|---|---|
| White blood cell count (×10/L) | 2.39 | 4.38 | 4–10 |
| Neutrophil (×10/L) | 1.47 | 2.25 | 2–7 |
| Lymphocyte (×10/L) | 0.61 | 1.51 | 0.8–4 |
| Eosinophil (×10/L) | 0 | 0.05 | 0.5–5 |
| Hypersensitive C-reactive protein (mg/L) | 3.8 | 0.1 | 0–5 |
| Procalcitonin (ng/mL) | 0.035 | 0–0.05 | |
| Red blood cell sedimentation rate (mm/h) | 17 | 11 | 0–15 |
| Alanine aminotransferase, ALT (U/L) | 20.5 | 5–40 | |
| Aspartate aminotransferase, AST (U/L) | 21.3 | 8–40 | |
| Creatinine (μmol/L) | 78 | 44–97 | |
| Rheumatologic and immunologic markers | |||
| Rheumatoid factor (IU/mL) | 5.71 | 0–18 | |
| Anti-CCP (RU/ml) | 3.35 | 0–20 | |
| Anti-U1RNP/Anti-ENA | Negative | Negative | |
| Anti-Sm | Negative | Negative | |
| Anti-SSA | Positive | Negative | |
| Anti-SSB | Negative | Negative | |
| Anti-Scl-70 | Negative | Negative | |
| Anti-Jo-1 | Negative | Negative | |
| Anti-rRNP | Negative | Negative | |
| Anti-double-stranded DNA | Negative | Negative | |
| Anti-nuclear antibody | Nuclear granular pattern (1: 80) | <1: 80 | |
| Anti-CCP, anti-cyclic citrullinated peptide antibody; Anti-U1RNP, anti-U1 ribonucleoprotein antibody; Anti-ENA, anti-extractable nuclear antigen antibody; Anti-Sm, anti-Smith antibody; Anti-SSA, anti-Sjögren syndrome antigen A antibody; Anti-SSB, anti-Sjögren syndrome antigen B antibody; Anti-Scl-70, anti-scleroderma 70 antibody; Anti-rRNP, anti-ribosomal ribonucleoprotein antibody. | |||